Physician profile
Benjamin E Kilpatrick
NPI 1326572074
$1,526.26
in general payments reported to CMS, 2019-2025
20 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $191 · 2023: $134 · 2024: $573 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $279.38 | 2023-2025 | Onpattro |
| Boston Scientific Corporation | $195.47 | 2021-2023 | Watchman Access System |
| Abbott Laboratories | $141.17 | 2023-2024 | Gallant |
| Novo Nordisk INC | $123.66 | 2024-2025 | Ozempic, Wegovy |
| Medtronic, INC. | $121.48 | 2022-2023 | Selectsecure |
| Lantheus Medical Imaging, INC. | $99.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $70.96 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $68.91 | 2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $54.30 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $52.64 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $49.88 | 2024-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $40.57 | 2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $38.26 | 2024-2025 | |
| Abiomed | $37.79 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.29 | 2024 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $32.23 | 2022 | |
| Amgen INC. | $31.69 | 2025 | Repatha |
| Lexicon Pharmaceuticals, INC. | $20.32 | 2024 | |
| Lilly USA, LLC | $17.00 | 2025 | Zepbound |
| Scpharmaceuticals INC. | $16.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kilpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.